

Virus Name: Sepik		Abbreviation: SEPV
Status Probable Arbovirus	Select Agent No	SALS Level 3
SALS Basis Insufficient experience with virus; i.e., experience factor from SALS surveys was less than 500 in laboratory facilities with low biocontainment.		
Other Information		
Antigenic Group B		

SECTION I - Full Virus Name and Prototype Number

Prototype Strain Number / Designation MK 7148	Accession Number	Original Date Submitted 11/23/1984
Family Flaviviridae	Genus Flavivirus	
Information From Ian D. Marshall	Address Dept. of Microbiology, JCSMR, Aust. Nat. Univ., Canberra, Australia	
Information Footnote Reviewed by editor		

Section II - Original Source

Isolated By (name) I.D. Marshall and G.M. Woodroffe	Isolated at Institute Canberra	
Host Genus Mansonia septempunctata	Species	Host Age/Stage Adult
Sex Female		
<u>Isolated From</u>	<u>Isolation Details</u>	
Signs and Symptoms of Illness	Arthropod	
Time Held Alive before Inoculation		
Collection Method Light trap	Collection Date 3/21/1966	
Place Collected (Minimum of City, State, Country) Timau, Sepik District, New Guinea		
Latitude 3° 40' S	Longitude 143° 7' E	
Macrohabitat Secondary tropical forest, low foothills adjoining Kunai grass plains	Microhabitat 4' from ground, overnight trapping	Method of Storage until Inoculated Liquid nitrogen and Revco at -70dC
Footnotes		

Section III - Method of Isolation

Inoculation Date
5/10/1966

Animal (Details will be in Section 6)
nb mice (Tissue Culture)

Route Inoculated ic and sc	Reisolation Yes
--------------------------------------	---------------------------

Other Reasons
Antigenically distinct from other group B viruses held in this lab.

Homologous Antibody Formation by Source Animal

Test(s) Used

Footnotes

Section IV - Virus Properties

Physicochemical

Pieces (number of genome segments)	Infectivity	Sedimentation Coefficients(s) (S)
Percentage wt, of Virion Protein	Lipid	Carbohydrate
Virion Polypeptides: Number	Details	
Non-virion Polypeptides: Number	Details	
Virion Density	Sedimentation Coefficients(s) (S)	
Nucleocapsid Density	Sedimentation Coefficients(s) (S)	

Stability of Infectivity (effects)

pH (infective range)

Lipid Solvent (ether - % used to test)	After Treatment Titer	Control Titer
Lipid Solvent (chloroform)	After Treatment Titer	Control Titer
Lipid Solvent (deoxycholate) 1:1000	After Treatment Titer <2.0 dex	Control Titer 5.2 dex
Other (formalin, radiation)		

Virion Morphology

Shape	Dimensions	
Mean nm	Range nm	
Measurement Method	Surface Projections/Envelope	Nucleocapsid Dimensions, Symmetry

Morphogenesis

Site of Constituent Formation in Cell

Site of Virion Assembly

Site of Virion Accumulation

Inclusion Bodies

Other

Hemagglutination

Hemagglutination

Antigen Source

Erythrocytes (species used)

Yes

SMB ext. by sucrose-acetone

Gander

pH Range

pH Optimum

6.0-6.8

6.2

Temperature Range

Temperature Optimum

35dC

Remarks

Serologic Methods Recommended

CF and NT

Footnotes

Mouse Immune Ascitic Fluids or Antigens	Sepik (MK 7148) Antigen			Sepik (MK 7148) Antiserum		
	HI	CF	NT	HI	CF	NT
	Ht/Ho	Ht/Ho	Ht/Ho	Ht/Ho	Ht/Ho	Ht/Ho
MVE	480/10240	5/80	1.0/5.0	320/320	<5/320	1.3/5.0
Kokobera	<10/1280	<5/40	0.7/3.0	160/320	5/320	0.5/5.0
Kunjin	1280/10240	<5/40	0.7/4.3	320/320	<5/320	0.5/5.0
Edge Hill	<10/320	20/320	0.4/1.0	160/320	10/320	0.5/5.0
Stratford	<10/20	<5/40	<0.5/0.7	120/320	<5/320	<0.5/5.0
JBE	640/1280	<5/160		40/320	<5/320	
Apoi *		<4/32			8/1024	
Langat		<4/32			8/1024	
Tembusu		16/512			16/1024	
Zika		4/32			4/1024	
Wesselsbron		8/8	2.7/4.5		512/1024	3.1/>4.5
West Nile		16/512			16/1024	
Dengue 1		<4/32			<4/1024	
Dengue 2		<4/32			<4/1024	
Dengue 3		4/4			<4/1024	
Dengue 4		<4/4			16/1024	

NT: LNI in dex.

* Tests from Apoi down were carried out at YARU by Dr. G.M. Woodroffe

Sepik virus is closely related to Wesselsbron virus but distinguishable by neutralization test from both South African and Thai strains of that virus.

Section VI - Biologic Characteristics

Virus Source (all VERTEBRATE isolates)

Lab Methods of Virus Recovery (ALL ISOLATIONS)
Newborn mice, chick embryo cell cultures

Cell system (a)	Virus passage history (b)	Evidence of Infection							Growth Without CPE +/- (g)
		CPE			PLAQUES				
		Day (c)	Extent (d)	Titer TCD50/ml (e)	Day (c)	Size (f)	Titer PFU/ml (e)		
Chick embryo (PC)						Plaques			

Section VII - Natural Host Range (Additional text can be added below table)

Vertebrate (species and organ) and arthropod	No. isolations/No. tested	No. with antibody/No. tested Test used	Country and region
Mansonia septempunctata	1/105		Sepik District, New Guinea
Ficalbia flavens and Ficalbia spp.	2/6,993		
Armigeres spp.	1/39		
Mixed mosquito pool	1		
Sheep		0/372 HI	Australia. Widely dispersed sites throughout New South Wales.

Section VIII - Susceptibility to Experimental Infection (include viremia)

Experimental host and age	Passage history and strain	Inoculation Route-Dose	Evidence of infection	AST	Titer
				(days)	log10/ml
Mice (nb)	SMB 4	ic 0.02	Death	7-9	8.7
Mice (nb)		ip 0.02	Death	7-9	8.0
Mice (nb)		sc			
Mice (wn)		ic 0.02	Death	8-15	7.7
Mice (wn)		ip 0.02	Antibodies		<3.0
guinea pigs (pregnant)		footpad	Transient low grade viremia in at least 2/12 mothers. Abortion rate no higher than in normal or JE and MVE inoculated controls. No virus in aborted fetuses of newborn.		

Section IX - Experimental Arthropod Infection and Transmission

Arthropod species & virus source(a)	Method of Infection log10/ml (b)		Incubation period (c)		Transmission by bite (d)		Assay of arthropod, log10/ml (e)		
	Feeding	Injected	Days	°C	Host	Ratio	Whole	Organ	System
	Mosquitoes infected by membrane feeding (1)								

Section X - Histopathology

Character of lesions (specify host)	
<u>Inclusion Bodies</u>	<u>Intranuclear</u>
Organs/Tissues Affected	
Category of tropism	

Section XI - Human Disease

In Nature Reported	Residual	Death
Subclinical	Overt Disease	
Clinical Manifestations Fever (R), headache (R)		
Number of Cases 1	Category (i.e. febrile illness, etc.) Febrile illness	

Section XII - Geographic Distribution

Known (Virus detected) Sepik District, New Guinea
Suspected (Antibody only detected)

Section XIII - References

1. Director, Queensland Inst. Ned. Res. Personal communication. 1973.

Remarks

One patient hospitalized with FUO showed rising neutralizing antibody titers.
--